These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25672711)

  • 21. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
    Echigoya Y; Mouly V; Garcia L; Yokota T; Duddy W
    PLoS One; 2015; 10(3):e0120058. PubMed ID: 25816009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development.
    Wu B; Benrashid E; Lu P; Cloer C; Zillmer A; Shaban M; Lu QL
    PLoS One; 2011; 6(5):e19906. PubMed ID: 21611204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.
    't Hoen PA; van der Wees CG; Aartsma-Rus A; Turk R; Goyenvalle A; Danos O; Garcia L; van Ommen GJ; den Dunnen JT; van Deutekom JC
    Pharmacogenomics; 2006 Apr; 7(3):281-97. PubMed ID: 16610940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.
    Aartsma-Rus A; Straub V; Hemmings R; Haas M; Schlosser-Weber G; Stoyanova-Beninska V; Mercuri E; Muntoni F; Sepodes B; Vroom E; Balabanov P
    Nucleic Acid Ther; 2017 Oct; 27(5):251-259. PubMed ID: 28796573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview on DMD exon skipping.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():97-116. PubMed ID: 22454057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exon skipping quantification by real-time PCR.
    Ferlini A; Rimessi P
    Methods Mol Biol; 2012; 867():189-99. PubMed ID: 22454062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Casimersen for Duchenne muscular dystrophy.
    Wilton-Clark H; Yokota T
    Drugs Today (Barc); 2021 Dec; 57(12):707-717. PubMed ID: 34909800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induced dystrophin exon skipping in human muscle explants.
    McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
    Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic potential of antisense-mediated exon skipping.
    van Ommen GJ; van Deutekom J; Aartsma-Rus A
    Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exon-skipping advances for Duchenne muscular dystrophy.
    Echevarría L; Aupy P; Goyenvalle A
    Hum Mol Genet; 2018 Aug; 27(R2):R163-R172. PubMed ID: 29771317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.
    Platenburg G
    Acta Myol; 2008 Oct; 27():69-73. PubMed ID: 19364065
    [No Abstract]   [Full Text] [Related]  

  • 35. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.
    Novak JS; Hogarth MW; Boehler JF; Nearing M; Vila MC; Heredia R; Fiorillo AA; Zhang A; Hathout Y; Hoffman EP; Jaiswal JK; Nagaraju K; Cirak S; Partridge TA
    Nat Commun; 2017 Oct; 8(1):941. PubMed ID: 29038471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Exon skipping in Duchenne's muscular dystrophy].
    Nau JY
    Rev Med Suisse; 2008 Jan; 4(140):176. PubMed ID: 18309885
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.
    Yokota T; Lu QL; Partridge T; Kobayashi M; Nakamura A; Takeda S; Hoffman E
    Ann Neurol; 2009 Jun; 65(6):667-76. PubMed ID: 19288467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.